Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)

Why It Matters

Poherdy introduces a lower‑cost alternative to Perjeta, expanding patient access and intensifying competition in the high‑priced oncology biologics market.

Key Takeaways

• Poherdy approved as interchangeable biosimilar for all Perjeta indications
• Approval backed by structural, PK, efficacy, safety, immunogenicity data
• Henlius gave Organon exclusive global rights, excluding China
• First biosimilar to Perjeta cleared in Europe, potentially lowering costs

Pulse Analysis

Biosimilars are reshaping oncology treatment economics, and pertuzumab—marketed as Perjeta—has long been a premium HER2‑targeted antibody. By replicating the reference molecule’s structure and function, Poherdy meets the rigorous standards set by European regulators, offering clinicians a therapeutically equivalent option without compromising safety. The EC’s endorsement underscores the maturity of biosimilar development pipelines, where sophisticated analytical techniques and comparative clinical trials now routinely satisfy interchangeability criteria.

The approval dossier for Poherdy combined high‑resolution structural analyses, pharmacokinetic bridging studies, and head‑to‑head clinical trials that confirmed comparable efficacy and immunogenicity profiles. Such comprehensive evidence not only satisfies regulatory thresholds but also builds physician confidence, a critical factor for adoption in hospitals and oncology centers. Interchangeable status further simplifies prescribing, allowing pharmacists to substitute Poherdy for Perjeta without additional physician authorization, streamlining supply chains and reducing administrative overhead.

Commercially, Henlius’s partnership with Organon positions Poherdy for rapid market penetration across Europe, leveraging Organon’s established sales network while Henlius retains manufacturing control. Excluding China from the agreement preserves Henlius’s domestic growth opportunities. For payers and patients, the entry of a biosimilar is expected to drive price competition, potentially lowering treatment costs by 20‑30 percent. This could broaden access to HER2‑positive breast cancer therapy, improve health‑system sustainability, and encourage further biosimilar investments in the oncology space.